checkAd
    Startseite > Aktien > ARS Pharmaceuticals > Nachrichten
    ARS Pharmaceuticals Aktie
    8,8900
     
    USD
    +1,72 %
    +0,1500 USD
    Letzter Kurs 02:00:00 Nasdaq
    8,8700
     
    USD
    400 STK
    Geldkurs 13.05.24
    8,8900
     
    USD
    100 STK
    Briefkurs 13.05.24
    ISIN: US82835W1080 · WKN: A2QHK9 · SYM: SPRY · USA

    Neueste Nachrichten

    ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results
    09.05.24 · globenewswire · ARS Pharmaceuticals
    ARS Pharmaceuticals Submits Response for neffy (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
    30.04.24 · globenewswire · ARS Pharmaceuticals
    ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy (Epinephrine Nasal Spray)
    03.04.24 · globenewswire · ARS Pharmaceuticals
    ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
    21.03.24 · globenewswire · ARS Pharmaceuticals
    ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy Investor Day
    07.03.24 · globenewswire · ARS Pharmaceuticals
    ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024
    06.03.24 · globenewswire · ARS Pharmaceuticals
    ARS Pharmaceuticals announces neffy meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study
    26.02.24 · globenewswire · ARS Pharmaceuticals
    ARS Pharmaceuticals to Host Virtual neffy Investor Day on March 7, 2024
    22.02.24 · globenewswire · ARS Pharmaceuticals
    ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter
    20.02.24 · globenewswire · ARS Pharmaceuticals
    ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy (epinephrine nasal spray) at 2024 AAAAI Annual Meeting
    05.02.24 · globenewswire · ARS Pharmaceuticals
    ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates
    09.11.23 · globenewswire · ARS Pharmaceuticals
    ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis
    09.11.23 · globenewswire · ARS Pharmaceuticals